The dilutive offering (~11% share count increase) is a near-term negative for existing shareholders, though the cash infusion supports the company's clinical pipeline.
NRXP drugs
NRXP drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 3 $4.05entry
- T+1 · 6mo ago 0.00%α −0.40% · $4.05
- T+5 · 5mo ago −7.16%α −3.34% · $3.76
- T+20 · 5mo ago −4.44%α −3.44% · $3.87
- T+60 · 3mo ago −10.62%α −13.12% · $3.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals priced an underwritten public offering of 5,714,286 shares at $3.50/share, with gross proceeds of ~$20.0M ($23.0M if underwriters fully exercise the 30-day option). The offering is dilutive (~11% of pre-offering shares) and proceeds are for working capital and general corporate purposes. The stock closed at $3.50 on June 3, 2026, indicating no premium/discount at pricing.
Key Financial Metrics
Key Facts
- Pricing of 5,714,286 shares at $3.50 per share
- Gross proceeds of approximately $20.0 million ($23.0 million if option exercised)
- Underwriters granted 30-day option to purchase up to 857,142 additional shares
- Offering expected to close June 4, 2026
- Proceeds for working capital and general corporate purposes
- BTIG, LLC is lead bookrunning manager; Lucid Capital Markets is joint bookrunning manager
- Offering made under effective shelf registration statement on Form S-3 (File No. 333-288205)
Financial Impact
~$20M gross proceeds from sale of ~5.7M shares, representing approximately 11% dilution based on pre-offering share count (implied by market cap of $167M and price of $3.50 = ~47.7M shares pre-offering).
Risk Factors
- Dilution of ~11% for existing shareholders
- Proceeds used for working capital, not specific pipeline milestone, signaling potential cash burn concerns
- Clinical-stage biopharma with no approved products; regulatory setbacks could severely impact valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306024 |
Track record
22 reports on NRXP
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers